Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Myelofibrosis symptoms compromise health-related quality of life (HRQoL). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue ruxolitinib due to loss of response or unacceptable toxicity. Fedratinib is an oral, selective JAK2 inhibitor approved in the United States f...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Jourdan, Eric, Silver, Richard T., Schouten, Harry C., Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Tang, Derek, Abraham, Pranav, Lord-Bessen, Jennifer, Rose, Shelonitda, Guo, Shien, Liao, Weiqin, Mesa, Ruben A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096470/
https://www.ncbi.nlm.nih.gov/pubmed/33969275
http://dx.doi.org/10.1097/HS9.0000000000000562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096470/
https://www.ncbi.nlm.nih.gov/pubmed/33969275
http://dx.doi.org/10.1097/HS9.0000000000000562

Ejemplares similares